Weaker immune response against COVID-19 may be attributed to the more targeted immunosuppressive mechanism of biologic DMARDs. Rheumatoid arthritis (RA) patients receiving biologic disease-modifying ...

Please provide your email address to receive an email when new articles are posted on . PHILADELPHIA — Patients with juvenile idiopathic arthritis started on conventional synthetic and biologic ...

A study looked at more than 23,600 Medicare beneficiaries with RA who had received a ≥30-day prescription of an opioid drug. Participants were grouped according to those who had been prescribed a ...

Please provide your email address to receive an email when new articles are posted on . Patients treated with tumor necrosis factor inhibitors experienced a shorter time until cancer progression.

Patients with psoriatic arthritis who received bDMARDs vs cDMARDs had a lower risk for major adverse cardiovascular events, all-cause mortality, and cardiovascular mortality. Biologic ...

Rheumatoid arthritis (RA) patients in Denmark with a history of solid tumor cancers, now in remission, faced no greater likelihood of cancer relapse when they were treated with biologic agents, ...

New research presented this week at ACR Convergence 2022, the American College of Rheumatology's annual meeting, found no significant difference in cancer risk in patients with rheumatic disease and a ...

ROME — Daily baricitinib, an oral Janus kinase (JAK)1/2 inhibitor, produces rapid clinical improvement in the signs and symptoms of rheumatoid arthritis in patients with active disease who have failed ...

BARCELONA -- Rheumatoid arthritis (RA) patients were exceedingly unlikely to develop refractory disease when their first medical therapy was a tumor necrosis factor (TNF) inhibitor, a researcher ...